Assignment history

Inventors

• Nikolaj Skak: Employer not explicitly stated in the patent, but was an assignor to LIFECYCLE PHARMA A/S and then VELOXIS PHARMACEUTICALS A/S.
• Per Holm: Employer not explicitly stated in the patent, but was an assignor to VELOXIS PHARMACEUTICALS A/S.

Unusual patterns: Not present. Nikolaj Skak and Per Holm were assignors to Lifecycle Pharma A/S and Veloxis Pharmaceuticals A/S, which aligns with the original assignee and its name change.

Original assignee

The entity named on the issued patent is Veloxis Pharmaceuticals AS (initially Lifecycle Pharma A/S, which changed its name to Veloxis Pharmaceuticals A/S).

Veloxis Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs for organ transplant recipients. They market Envarsus XR® (tacrolimus extended-release tablets), which embodies the claims of this patent.

Current status: Operating. Veloxis Pharmaceuticals Inc. is an active, operating company.

Assignment timeline

• 2011-03-10 (executed) / recorded 2011-03-25 — Reel 026024/0570

  • Conveyance: ASSIGNMENT
  • Assignor: SKAK, NIKOLAJ and HANSEN, LISELOTTE
  • Assignee: LIFECYCLE PHARMA A/S, DENMARK
  • Correspondent: KENNETH F REICK, REICK AND CHAPPELL, P.C., P.O. BOX 1007, BOULDER, CO 80306
  • Context: Transfer of inventors' interests to the original assignee.

• 2011-07-14 (executed) / recorded 2011-07-15 — Reel 026598/0929

  • Conveyance: CHANGE OF NAME
  • Assignor: LIFECYCLE PHARMA A/S
  • Assignee: VELOXIS PHARMACEUTICALS A/S, DENMARK
  • Correspondent: KENNETH F REICK, REICK AND CHAPPELL, P.C., P.O. BOX 1007, BOULDER, CO 80306 (This correspondent recurs in this chain.)
  • Context: Internal reorg, change of company name.

• 2013-05-15 (executed) / recorded 2013-10-02 — Reel 031327/0467

  • Conveyance: ASSIGNMENT
  • Assignor: HOLM, PER
  • Assignee: VELOXIS PHARMACEUTICALS A/S, DENMARK
  • Correspondent: KENNETH F REICK, REICK AND CHAPPELL, P.C., P.O. BOX 1007, BOULDER, CO 80306 (This correspondent recurs in this chain.)
  • Context: Transfer of inventor's interest to the assignee.

• 2018-02-14 (executed) / recorded 2018-02-15 — Reel 044942/0597

  • Conveyance: SECURITY INTEREST
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: ATHYRIUM OPPORTUNITIES III ACQUISITION LP, NEW YORK
  • Correspondent: MORRISON & FOERSTER LLP, 250 WEST 55TH STREET, NEW YORK, NEW YORK 10019
  • Context: Securitization (loan collateral).

• 2020-01-23 (executed) / recorded 2020-01-23 — Reel 051602/0704

  • Conveyance: RELEASE BY SECURED PARTY
  • Assignor: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
  • Assignee: VELOXIS PHARMACEUTICALS A/S, DENMARK
  • Correspondent: MORRISON & FOERSTER LLP, 250 WEST 55TH STREET, NEW YORK, NEW YORK 10019 (This correspondent recurs in this chain.)
  • Context: Release of security interest.

• 2020-12-30 (executed) / recorded 2021-03-17 — Reel 055613/0695

  • Conveyance: ASSIGNMENT
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC., NORTH CAROLINA
  • Correspondent: JENSEN AND HIATT, PLLC, 8180 SOUTH 700 EAST, SUITE 350, SANDY, UTAH 84070
  • Context: Internal reorg, likely a change of corporate structure or domicile.

• 2020-12-30 (executed) / recorded 2021-04-02 — Reel 055815/0597

  • Conveyance: ASSIGNMENT
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC., NORTH CAROLINA
  • Correspondent: JENSEN AND HIATT, PLLC, 8180 SOUTH 700 EAST, SUITE 350, SANDY, UTAH 84070 (This correspondent recurs in this chain.)
  • Context: Internal reorg, likely a duplicate or clarification of the previous assignment due to the same execution date.

• 2024-06-07 (executed) / recorded 2024-06-07 — Reel 067666/0352

  • Conveyance: CHANGE OF ADDRESS
  • Assignor: VELOXIS PHARMACEUTICALS INC.
  • Assignee: VELOXIS PHARMACEUTICALS INC., NORTH CAROLINA
  • Correspondent: JENSEN AND HIATT, PLLC, 8180 SOUTH 700 EAST, SUITE 350, SANDY, UTAH 84070 (This correspondent recurs in this chain.)
  • Context: Change of address for the current assignee.

Timeline diagram

timeline
    title Ownership of US 9549918
    2011 : Inventors to Lifecycle Pharma A/S
         : Lifecycle Pharma A/S becomes Veloxis A/S
    2013 : Inventor Holm to Veloxis A/S
    2018 : Security interest to Athyrium
    2020 : Security interest released
    2021 : Veloxis A/S to Veloxis Inc
    2024 : Veloxis Inc address change

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The transfers involve Lifecycle Pharma A/S (which became Veloxis Pharmaceuticals A/S) and then Veloxis Pharmaceuticals Inc., both operating companies. Athyrium Opportunities III Acquisition LP appears to be a legitimate investment fund providing financing (security interest), not a shell entity for assertion.
2. Known asserter in the chain — not present. None of the assignees (Lifecycle Pharma A/S, Veloxis Pharmaceuticals A/S, Athyrium Opportunities III Acquisition LP, Veloxis Pharmaceuticals Inc.) match known NPE lists.
3. Repeat correspondent across the chain — present.
   • KENNETH F REICK, REICK AND CHAPPELL, P.C. appears on Reels 026024/0570, 026598/0929, and 031327/0467.
   • MORRISON & FOERSTER LLP appears on Reels 044942/0597 and 051602/0704.
   • JENSEN AND HIATT, PLLC appears on Reels 055613/0695, 055815/0597, and 067666/0352.
     While the presence of repeat correspondents is a signal, in this case, it appears to be indicative of consistent legal counsel for the operating companies (Lifecycle/Veloxis) and their financing partners (Morrison & Foerster for Athyrium), rather than a sign of NPE activity.
4. Cascading transfers — not present. The transfers are spaced out over years, reflecting corporate actions rather than rapid patent aggregation for assertion.
5. Pre-litigation transfer — unclear. The case 1:22-cv-00909 was filed on July 7, 2022. The last assignment to Veloxis Pharmaceuticals Inc. was recorded on March 17, 2021, and April 2, 2021, which is more than 6 months prior to the litigation. However, the litigation summary also states "Filing Date: Not specified, but active in 2026." for the Sun Pharma case and April 14, 2025, for the Glenmark case. The earliest recorded litigation for this patent is July 7, 2022 (case 1:22-cv-00909). The assignments in 2021 (Reel 055613/0695 and 055815/0597) occurred more than 6 months before this earliest recorded litigation.
6. Bankruptcy fire-sale — not present. There is no indication of bankruptcy proceedings for Lifecycle Pharma A/S or Veloxis Pharmaceuticals.
7. Privateering — not present. All identified litigation is initiated by Veloxis Pharmaceuticals Inc., an operating company, against generic drug manufacturers, which is a standard operating-company assertion model.
8. Defensive aggregator (anti-NPE) — not present. The patent is currently held by an operating company that is asserting it.

Verdict

Operating-company assertion. The patent has been consistently held by Veloxis Pharmaceuticals (or its predecessor Lifecycle Pharma), which manufactures and sells a product embodying the claims (Envarsus XR®). The litigation is against generic drug manufacturers, which is typical of operating companies defending their market. The repeated correspondents are consistent with the ongoing legal representation of an operating entity through corporate changes and financial transactions.

USPTO Assignment Center search page for US9549918